Shionogi, Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1919-01-01

Employees: -

Market Cap: $13.1B

Website: https://www.shionogi.com/jp/ja/

Clinical Trials

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Phase 2

Completed

Conditions: Opioid Induced Bowel Dysfunction

Interventions: Drug: Naldemedine
Drug: Placebo

First Posted Date: 2010-05-12

Last Posted Date: 2017-05-30

Lead Sponsor: Shionogi

Target Recruit Count: 72

Registration Number: NCT01122030

Locations: 🇺🇸
Shionogi Research Site, Salt Lake City, Utah, United States

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Phase 2

Terminated

Conditions: Immune Thrombocytopenia (ITP)

Interventions: Drug: Placebo
Drug: Lusutrombopag

First Posted Date: 2010-01-22

Last Posted Date: 2021-03-18

Lead Sponsor: Shionogi

Target Recruit Count: 20

Registration Number: NCT01054443

Locations: 🇺🇸
Investigator, Seattle, Washington, United States

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: S-2367 (velneperit)

First Posted Date: 2008-11-11

Last Posted Date: 2018-05-01

Lead Sponsor: Shionogi

Target Recruit Count: 766

Registration Number: NCT00788528

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: S-2367 Placebo
Drug: S-2367 1600 mg q.d. 60 weeks
Drug: S-2367 1600 mg q.d. 54 Weeks
Other: LCD (low calorie diet)
Other: RCD (reduced calorie diet)

First Posted Date: 2008-09-08

Last Posted Date: 2018-05-11

Lead Sponsor: Shionogi

Target Recruit Count: 842

Registration Number: NCT00748605

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: S-2367 800 mg
Drug: S-2367 Placebo
Drug: S-2367 1600 mg
Other: Reduced Calorie Diet

First Posted Date: 2008-09-08

Last Posted Date: 2018-05-11

Lead Sponsor: Shionogi

Target Recruit Count: 724

Registration Number: NCT00747929

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Phase 3

Completed

Conditions: Vaginal Diseases
Atrophy

Interventions: Drug: Ospemifene 60 mg
Drug: Placebo

First Posted Date: 2008-08-07

Last Posted Date: 2018-05-18

Lead Sponsor: Shionogi

Target Recruit Count: 919

Registration Number: NCT00729469

Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: CLONICEL (Clonidine HCl sustained release)

First Posted Date: 2008-07-28

Last Posted Date: 2018-04-18

Lead Sponsor: Shionogi

Target Recruit Count: 303

Registration Number: NCT00723190

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: S-777469 800 mg
Drug: S-777469 400 mg
Drug: Placebo

First Posted Date: 2008-06-23

Last Posted Date: 2018-05-08

Lead Sponsor: Shionogi

Target Recruit Count: 209

Registration Number: NCT00703573

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: 50 mg S-777469
Drug: 200 mg S-777469
Drug: 800 mg S-777469
Drug: Placebo

First Posted Date: 2008-06-16

Last Posted Date: 2018-05-01

Lead Sponsor: Shionogi

Target Recruit Count: 37

Registration Number: NCT00697710

Locations: 🇺🇸
Comprehensive Phase One, Miramar, Florida, United States

A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

Phase 2

Completed

Conditions: Atrophy
Vaginal Diseases

Interventions: Drug: Placebo
Drug: Ospemifene 5 mg
Drug: Ospemifene 15 mg
Drug: Ospemifene 30 mg

First Posted Date: 2008-03-07

Last Posted Date: 2013-06-28

Lead Sponsor: Shionogi

Target Recruit Count: 126

Registration Number: NCT00630539

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy